

# OFF-X

## Anticipate risk and drive competitive value with advanced drug safety intelligence

- Anticipate the safety of novel targets based on up/downstream genes in their signaling pathways
- Anticipate off-target toxicities of new compounds based on their secondary pharmacology
- Benchmark daily updated safety profiles of investigational, launched and discontinued products
- Discover mechanisms behind unexpected adverse events
- Support signal detection, prioritization and validation based on class intelligence

Filter		Columns	View AE/SOC	Heat map Number of alerts	Sort drugs Highest phase																				
Adverse event • System Organ Class					vetorralb Launched 2021	adagrasib Launched 2022	D-1553 Phase I/II	divaralib Phase I	ERAS-4093	ERAS-5024	GEC255	GPH-925 Phase I/II	HMS-4642 Phase I	JAB-21822 Phase I/II	JQ043 Phase III	MLA-74609157 Phase I	MK-1084 Phase I	BMC-6236 Phase I	BMC-6291 Phase I	salirasib Phase II	OS19018	ASP-3082 Phase I	BB-17101943 Phase I	Tools	
<div><div></div><div>OFF-X Target/Class Score</div><div></div></div>																									
Alanine aminotransferase increased • Investigations					High	32	17	4	4	1	2	1	2	1	1	2		1	2		2	1			<div><div></div><div></div></div>
→ Aspartate aminotransferase increased • Investigations					High	34	16	4	4	1	2	1	2	1	1	2	1	1	2	1	3	1			<div><div></div><div></div></div>
Diarrhoea • Gastrointestinal disorders					High	43	21	4	4			1	1		1	2		1	3	1	6	1		1	<div><div></div><div></div></div>
Nausea • Gastrointestinal disorders					High	28	21	3	4			1				2		1	3	1	4	1		1	<div><div></div><div></div></div>
Vomiting • Gastrointestinal disorders					High	20	21	2	4		1	1	1		1	2		1	3	1	2	1		1	<div><div></div><div></div></div>
Abdominal pain • Gastrointestinal disorders					Medium	13	6		1												3			1	<div><div></div><div></div></div>
Anaemia • Blood and lymphatic system disorders					Medium	23	16	2	1			1	2	1	1			1			1			1	<div><div></div><div></div></div>
Blood albumin decreased • Investigations					Medium	1	1			1	1														<div><div></div><div></div></div>
Blood alkaline phosphatase increased • Investigations					Medium	22	7	2	1		1		1				1	1			1	1		1	<div><div></div><div></div></div>
Blood bilirubin increased • Investigations					Medium	10	2	2		1		2		1							3				<div><div></div><div></div></div>
Blood creatinine increased • Investigations					Medium	6	13					1									2				<div><div></div><div></div></div>
Blood sodium decreased • Investigations					Medium	3	1			1	1														<div><div></div><div></div></div>


## Key Questions

- How can we anticipate the toxicity of novel targets?
- How can we anticipate adverse events related to our drugs in development based on other members of the class?
- How can we anticipate the safety of novel combinations?
- How can we assess drug vs class effects?
- How can we assess on-target vs off-target effects?
- How can we stay abreast of new safety-related data reported daily in a broad range of data sources for our drugs and targets of interest?

## Features and data sources

- Unique combination of manually curated data and analytics to quickly understand the safety liabilities of a given drug or target
- Keep your target safety assessments updated
- Compare the safety profile of Drugs and Target/Classes
- Discover how preclinical findings can translate into the clinic and impact trial outcomes
- Compare safety data extracted from the drug labels of different regulatory bodies
- Assess the safety profile of drugs and targets based on patient population (age, gender, ethnicity) and condition
- Save time assessing and understanding new safety signals with a unique integration of literature,<sub>1</sub> regulatory data and RWD

# OFF-X: leveraging safety intelligence to drive competitive advantage



## OFF-X fast facts

- Expertly curated toxicity and safety intelligence coupled with advanced analytics
- One-stop-shop to monitor and anticipate safety liabilities across all phases of drug R&D and post-marketing
- Over 3,000,000 manually curated safety alerts, 15,500 targets, 40,000 drugs/biologics/combinations and 14,000 toxicity and adverse event endpoints
- Comprehensive range of sources of information including regulatory, literature, scientific congresses, clinical trial registries and company communications
- Covering small molecules, mAbs, ADCs, BiTEs, gene & cell therapies, mRNA vaccines, etc.
- Updated daily / Set up alerts for drugs and targets of interest

System Organ Class	OFF-X Target/Class Score	Biological Role & Preclinical Pharmacological Evidence			Clinical Pharmacological Evidence					
		Target Expression	In vitro Data / Patient samples	Preclinical	Phase I	Phase II	Phase III	Clinical Regulatory	Postmarketing	
Investigations	High		Species 1: 2, 2	Species 4: 118, 14	214, 17	148, 5	57, 2	37, 1	20, 2	
Gastrointestinal disorders DME	High			Species 2: 7, 2	212, 17	119, 6	39, 2	28, 2	12, 1	
General disorders and administration site conditions DME	Medium			Species 4: 9, 7	66, 14	60, 4	21, 2	21, 2	7, 2	
Metabolism and nutrition disorders	Medium			Species 3: 10, 3	66, 15	39, 5	20, 2	10, 1	4, 1	
Blood and lymphatic system disorders DME	Medium			Species 3: 6, 2	48, 13	28, 4	9, 2	6, 2	5, 1	
Skin and subcutaneous tissue disorders DME	Medium									
Nervous system disorders DME	Medium									

